Validation of the Special Projects of National Significance Adherence Tool in HIV/AIDS Patients

Abstract

Spanish

French

Background:

Adherence to highly active antiretroviral therapy (HAART) is crucial for success. Therefore, having validated tools to help assess adherence is necessary. The Health Resources and Services Administration assessed adherence as a Special Project of National Significance (SPNS). As a result of their study, a 3-question survey was developed as a simple tool to assess adherence in patients with HIV/AIDS.

Objective:

To validate the SPNS adherence survey as an accurate and effective way to assess adherence and to determine whether any other independent variables correlate with a significant reduction in viral load.

Methods:

The study was a retrospective chart review of 300 patients actively enrolled in an HIV/AIDS clinic from January 2007 to September 2007. Patients were eligible for the study if they had been on HAART for at least 6 months, were 2:18 years old, and had completed at least 2 surveys.

Results:

A total of 74 patients met the criteria; the majority were male (75.3%) and African American (91.9%). Twenty-six (35.1%) patients had scores ≤10, indicating poorer adherence, and 48 (64.9%) patients had scores ≤11. The mean number of antiviral plus other medications was 4.4. Dosing of HAART drugs was once (5 nonadherent, 23 adherent pts.) and twice (21,25 pts., respectively) daily, and mean number of different antiretroviral tablets/capsules being taken was 1.7 and 1.5, respectively, The nonadherent patients’ average viral load was 15,202.3 copies/mL, while the adherent patients’ average viral load was 163.8 copies/mL (p = 0.001) The SPNS score was significantly associated with HIV-RNA viral load (-0.482, p < 0.001), There also was a significant association between a higher HIV-RNA viral load and the total number of medications a patient was taking, as well as the number of different antiretroviral tablets/capsules being taken (0.299, p = 0.01; 0.249, p = 0.03). There was no significant difference in HIV-RNA viral load when comparing age, sex, race, income, and frequency of HIV drug dosing.

Conclusions:

The SPNS survey is a valid and simple tool in measuring adherence that can aid health-care professionals in assessing adherence to HAART.

Keywords

adherence AIDS HIV SPNS survey

Get full access to this article

View all access options for this article.

References

Paterson

, Swindells

, Mohr

. Adherence to protease inhibitor therapy and outcomes in patients with HIV infections. Ann Intern Med 2000;133:21–30.

Gardner

, Sharma

, Peng

. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008;22:75–82.

Shin

, Munoz

, Espíritu

. Psychosocial impact of poverty on antiretroviral nonadherent among HIV-TB coinfected patients in Lima, Peru. J Int Assoc Physicians AIDS Care (Chic Ill) 2008;7:74–81.

Nau

, Aikens

, Pacholski

. Effects of gender and depression on oral medication adherence in persons with type 2 diabetes mellitus. Gend Med 2007;4:205–13.

Carrieri

, Leport

, Protopopescu

. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006;41:477–85.

Remien

, Hirky

, Johnson

. Adherence to medication treatment a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav 2003;7:61–72.

Trotta

, Ammassali

, Melzi

. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002;31:S128-31.

Heath

, Singer

, O'shaughnessy

, Montaner

, Hogg

. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:211–7.

Bnesacher

, Gurwltz

, Soumeral

. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 2007;22:864–71.

10.

Stone

, Adelson-Mitty

, Duefield

. Adherence to protease inhibitors in clinical practice: usefulness of demographics, attitudes, and knowledge as predictors (abstract 32337). Int Conf AIDS 1998;12:588.

11.

Ribaudo

, Haas

, Tierney

. Adult AIDS Clinical Trials Group Study. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006;42:401–7.

12.

Torno

, Witt

, Saitoh

, Fletcher

. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy 2008;28:782–7.

13.

Kalichman

, Amarai

, Stearns

. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med 2007;22:1003–6.

14.

Health Resources and Services Administration. HRSA Care Action. http://hab.hrsa.gov/publications/may2005/ (accessed 2008 Oct 12).

15.

The assessment of reliability. In: Nunnally

, Bernstein

, eds. Psychometric theory. 3rd ed. New York: McGraw-Hill, 1994:248-92.

16.

Glass

, DeGeest

, Hirschel

. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. AntivirTher2008;13:77-85.

17.

Mannheimer

, Thackeray

, Huppler Hullsiek

. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care 2008;20:161–9.

18.

Wang

, He

, Li

. Self-reported adherence to antiretroviral treatment among HIV-infected people in Central China. AIDS Patient Care STDS 2008;22:71–80.

19.

Murri

, Ammassali

, Gallicano

. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000;24:123–8.

20.

Liu

, Miller

, Hays

. A comprehensive evaluation of survey questions for adherence to antiretroviral medications and exploratory analyses for identifying optimal sets of survey questions. AIDS Patient Care STDS 2006;20:760–72.